Drug Profile
Research programme: Huntington's disease therapeutics - Siena Biotech
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Siena Biotech
- Class
- Mechanism of Action HD protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in Italy
- 23 Feb 2011 Preclinical trials in Huntington's disease in Italy (unspecified route)